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Summary
Objective: Nitric oxide (NO) produced by cartilage and synovial membranes is implicated in the pathogenesis of osteoarthritis (OA) and
inhibitors of NO synthesis may have indications in the treatment or prevention of joint destruction in OA. Because the signaling mechanisms
as well as the NOS isoform involved in induction of NO production in human cartilage remain in many parts unclear, the present study was
designed to investigate the regulation of inducible NO synthesis in human intact OA cartilage.
Methods: Cartilage specimens were collected from OA patients undergoing knee replacement surgery and studied for iNOS expression and
NO production in organ culture to allow intact chondrocyte–matrix interactions. J774 macrophages were used for comparison as a
well-documented source of iNOS.
Results: OA cartilage expressed iNOS and produced NO in the absence of exogenous cytokines. Addition of interleukin-1 (IL-1),
tumor necrosis factor  (TNF) or lipopolysaccharide (LPS) into the culture medium enhanced NO production in a dose-and time-
dependent manner. Various NOS inhibitors suppressed NO production in the following order of potency: 1400W (novel selective iNOS
inhibitor)=L-NIO>L-NMMA>L-NAME. Cycloheximide (an inhibitor of protein synthesis), pyrrolidine dithiocarbamate (PDTC; an NF-B
inhibitor) and genistein (an inhibitor of tyrosine protein kinases) inhibited cytokine-induced NO production, while dexamethasone,
diaminohydroxypyrimidine (DAHP; an inhibitor of tetrahydrobiopterin synthesis) and PD 98059 (p42/44 MAP kinase inhibitor) had no effect.
Conclusions: The results suggest that NO synthesis in human osteoarthritic cartilage derives from the glucocorticoid-insensitive expression
of iNOS. Very similar mechanisms appear to regulate inducible NO synthesis in human osteoarthritic cartilage and J774 macrophages with
the exception that dexamethasone inhibited NO production in J774 cells but not in osteoarthritic cartilage. © 2001 OsteoArthritis Research
Society International
Key words: Nitric oxide, Cartilage, Osteoarthritis, Pharmacology.Received 5 May 2000; revision requested 14 September 2000;
revision received 7 February 2001; accepted 26 February 2001.
Author correspondence to: Eeva Moilanen, MD, Professor of
Pharmacology, University of Tampere, Medical School, 33014
University of Tampere, Finland. Tel: +358 3 215 6741; Fax: +358
3 215 8082; E-mail: eeva.moilanen@uta.fiIntroduction
NO acts as a mediator in various physiological and patho-
physiological processes in the body1. In the inflammatory
reaction NO has both regulatory and cytotoxic effects2. In
inflamed joints, NO acts principally as a proinflammatory
and destructive mediator. NO activates metalloproteases3,
inhibits collagen and proteoglycan synthesis4–7 and
induces chondrocyte apoptosis8–10. NO is also involved
indirectly in the up-regulation of proinflammatory cytokine
production in the inflamed joints by reducing the synthesis
of IL-1 receptor antagonist (IL-1Ra)11 and by increasing the
production of TNF by synovial cells12. Recently, a selec-
tive inhibitor of iNOS, L-NIL, was found to slow down the
progression of experimentally induced osteoarthritis (OA)13
suggesting that inhibitors of induction or activity of NOS597in articular cartilage may provide a novel therapeutic
approach in the treatment of OA.
Induction of NO synthesis in rabbit articular chondro-
cytes was first demonstrated in 199114 and two years later
this was extended to human chondrocytes15–17. Nitrite
levels in synovial fluid are elevated in patients with OA and
rheumatoid arthritis (RA), suggesting an increased NO
synthesis in both degenerative and inflammatory joint dis-
orders18. In inflamed joints, iNOS is expressed also in
synovial membrane19 and in the pseudo-synovial mem-
brane around loosened joint implants20. A recent immuno-
histochemical study reported enhanced expression of
iNOS principally in chondrocytes and significantly less in
synovial cells in OA patients suggesting that chondrocytes
are the major source of NO in osteoarthritic joints21. In
addition to the 131 kDa human iNOS that was first found
and cloned in human chondrocytes15–17, another NO syn-
thase was described by Amin et al. (1995)22 in human
osteoarthritic cartilage. This enzyme, called OA-NOS, is
reported to be different from iNOS and relatively close to
nNOS in its molecular weight and antibody binding22. The
sequence of OA-NOS is not yet known and it is not clear if
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PATIENTS, TISSUE AND CELL CULTURES
Cartilage tissue was obtained from the leftover pieces of
total knee replacement surgery. The study protocol was
approved by the ethics committee of Tampere University
Hospital. The donor patients, ages ranging from 48 to 88
years, were all diagnosed as having OA. Full thickness
pieces of articular cartilage were removed aseptically from
subchondral bone with a scalpel and cut into small pieces.
These pieces of cartilage were incubated at 37°C in humidi-
fied 5% carbon dioxide atmosphere in Dulbecco’s modified
Eagle medium (DMEM) supplemented with 10% heat-
inactivated fetal bovine serum, penicillin (100 units/ml),
streptomycin (100 g/ml) and amphotericin B (250 ng/ml)
(Gibco BRL, Paisley, Scotland, U.K.). J774 murine
macrophages were cultured under similar conditions and
harvested with trypsin-EDTA (EDTA=ethylenediaminetetra-
acetic acid; Gibco BRL, Paisley, Scotland, U.K.).NITRITE DETERMINATION
The culture medium was collected after the time indi-
cated and nitrite, a stable product of NO in aqueous
solutions, was measured using the Griess reaction23. In
some experiments nitrite was also determined by the
ozone-chemiluminesence method, with very similar results
(data not shown). Tissue pieces were weighed and results
were expressed as nitrite pmol/mg tissue.IMMUNOHISTOCHEMISTRY
Immunolocalization of iNOS was carried out on cryostat
sections of the cartilage tissue specimens collected during
joint replacement operations in seven patients. Cryostat
sections 5–6 m thick were cut from different blocks from
each patient. The sections were fixed briefly for 5 min in
acetone/methanol fixative (50/50) at −20°C and washed
with 0.05 M/L Tris-HCl buffered saline pH 7.6 (TBS) andimmunostained with the biotin-streptavidin alkaline phos-
phatase technique as previously described20. The sections
were incubated for 18 h with the primary antibodies that
included the polyclonal sheep IgG antibody to human iNOS
(1/500), the chondrocyte marker 5B5 (1/100), and the
negative control normal sheep IgG. This was followed by
1 h incubation with biotinylated rabbit anti-sheep IgG anti-
body; sections stained with the 5B5 monoclonal antibody
were incubated with biotinylated horse anti-mouse IgG
antibody. Alkaline phosphatase streptavidin conjugate was
added to all slides for 1 h incubation. The substrate reac-
tion was developed using Naphthol AS-BI phosphate and
Fast Red TR salt. Levamisole was used at concentration
of 10 mM as an inhibitor of endogenous alkaline phos-
phatase. To confirm the specificity of the immunostaining,
the primary antibody was replaced with TBS in one
section. In addition two sections from each cartilage were
stained with the substrate solution with or without levami-
sole to exclude the possibility of non-spesific labeling of
endogenous alkaline phosphatase.WESTERN BLOT ANALYSIS
Frozen cartilage specimen milled with Micro-
Dismembrator and cell pellets from J774 cells were lysed in
ice-cold extraction buffer (10 mM Tris-base, 5 mM EDTA,
50 mM NaCl, 1% Triton-X-100, 0.5 mM phenylmethylsulfo-
nylfluoride, 2 mM Na-orthovanadate, 10 g/ml leupeptin,
25 g/ml aprotin, 1.25 mM NaF, 1 mM Na-pyrophosphate,
10 mM n-octyl--D-glucopyranoside; all from Sigma, St
Louis, MO, U.S.A.). Following incubation in ice for 15 min,
samples were centrifuged and the resulting supernatant
boiled for 5 min in sample buffer (62.5 mM Tris-HCl, 20%
glycerol, 2% SDS and 10 mM 2-mercapto-ethanol; all from
Sigma, St Louis, MO, U.S.A.) and stored at −20°C until
analysed. An aliquot of the supernatant was used to
measure the protein concentration by the Coomassie blue
method24. Protein samples (10 g) were separated by
SDS-PAGE on 10% polyacrylamide gels and transferred to
nitrocellulose. INOS protein was identified by Western blot
using rabbit polyclonal iNOS antibody (N-20) obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). This
antibody is raised against a peptide corresponding to an
amino acid sequence mapping the amino terminus of
human iNOS. It reacts with iNOS of mouse, rat and human
origin and there is no cross-reactivity with neuronal or
endothelial NOS. The molecular weight was estimated
using molecular weight standards (Precision Prestained
Standards; Bio-Rad, Hercules, CA, U.S.A.).STATISTICAL ANALYSIS
Results are expressed as mean±standard error of the
mean (S.E.M.). Statistical significance was calculated by
ordinary or repeated measures analysis of variance fol-
lowed by Bonferroni multiple comparisons test or by
Friedman non-parametric repeated measures test followed
by Dunn’s multiple comparisons test. Differences were
considered significant when P<0.05.REAGENTS
IL-1 was purchased from Genzyme, Cambridge, MA,
U.S.A. and TNF from Immugenex Corp. (Los Angeles,
CA, U.S.A.). Affinity purified polyclonal sheep IgG antibodyit is a novel isoform of NOS or a modification of one of
the earlier documented isoforms, either iNOS or nNOS.
Inhibitors of cartilage NOS expression and NO synthesis
have potential in the prevention of joint destruction,
especially if osteoarthritic cartilage NOS were differently
regulated than other isoforms of NOS. Selective inhibition
of cartilage NOS would then have significant therapeutic
implications.
Most of the studies on the regulation of NOS expression
and NO production in chondrocytes have been done in
cultures of isolated cells17. It is known that extracellular
matrix regulates chondrocyte metabolism in intact carti-
lage. In cell culture, the phenotype of isolated chondrocytes
alters rapidly and the chondrocytes begin to proliferate.
Therefore the data from studies with cultured chondrocytes
are not directly applicable for intact osteoarthritic cartilage.
The aim of the present study was to characterize the NOS
isoform in intact osteoarthritic cartilage by studying the
regulation of its expression and its sensitivity to various
NOS inhibitors. The results suggest that in intact osteo-
arthritic cartilage IL-1-induced NO production results
from the glucocorticoid-insensitive expression of iNOS,
the activity of which is effectively blocked by a recently
developed selective iNOS inhibitor, 1400W.
Osteoarthritis and Cartilage Vol. 9, No. 7 599to human iNOS was a gift from Dr I. Charles. The
monoclonal antibody 5B5 to the -subunit of prolyl-4-
hydroxylase, a marker of fibroblasts and chondrocytes, was
purchased from Dako. Bacterial lipopolysaccharide (LPS),
cycloheximide, NG-nitro-L-arginine methyl ester (L-NAME)
and genistein were from Sigma, St Louis, MO, U.S.A.
N-monomethyl-L-arginine (L-NMMA; Clinalfa, La¨ufelfingen,
Switzerland), L-N-iminoethyl-ornithine (L-NIO) and 1400W
(Glaxo Wellcome, Stevenage, U.K.), dexamethasone
(Orion Corp., Espoo, Finland), PD 98059 (Calbiochem-
Novabiochem Corporation, La Jolla, Canada), pyrrolidine
dithiocarbamate (PDTC) and diaminohydroxypyrimidine
(DAHP; Tocris, Langford, Bristol, U.K.) were obtained as
indicated.ResultsSPONTANEOUS NITRIC OXIDE PRODUCTION BY OA CARTILAGE
OA cartilage produced low concentrations of nitrite in
organ culture in the absence of exogenous cytokines [Fig.
1(a)]. Nitrite accumulation was linear up to 72 h follow-up
and it was partly inhibitable with a nitric oxide synthase
(NOS) inhibitor L-NIO at 1 mM concentrations suggesting
that NO was produced by the unstimulated cartilage.Human iNOS expression was also assessed by Western
blotting (see Fig. 4), and by immunohistochemistry in
sections of cartilage from seven OA patients undergoing
joint replacement operation. All sections demonstrated
positive labeling of the chondrocytes for  subunit of
prolyl-4-hydroxylase with the Mab 5B5. The purified sheep
antibody to iNOS used in this study showed high intensity
of immunoreactivity with more than 70% of chondrocytes in
the cartilage sections from the seven patients [Fig. 1(b)].
The majority of the single chondrocytes within the super-
ficial outer surface of the cartilage were positive. In the
deeper layers the staining was less uniform, and was seen
in chondrocytes within the clusters of the adjacent lacunae
or doublets (2–4 cells in one lacuna). The staining was
almost restricted to perinuclear cytoplasm. No positive
staining was observed outside the lacunae in any of the
cases.0
72
200
Time (h)
A
N
it
ri
te
 (
pm
ol
/m
g 
ca
rt
il
ag
e)
8
150
100
50
4824
**
*
**
*
Fig. 1. (a) Nitrite production by osteoarthritic cartilage in the absence of exogenous cytokines (––) and the inhibitory effect of NOS inhibitor
L-NIO (1 mM, ––). Mean±S.E.M., 7 patients, each with 6 replicates. Statistical significance was calculated by Friedman non-parametric
repeated measures test followed by Dunn’s multiple comparisons test. *** indicates P<0.001 as compared to samples incubated in the
presence of L-NIO (N=7 was used in statistical analysis). (b) Immunohistochemical section showing positive staining for iNOS in
osteoarthritic cartilage.CYTOKINE STIMULATED NITRIC OXIDE PRODUCTION BY OA
CARTILAGE
Proinflammatory cytokines IL-1 (0.04–4 ng/ml) and
TNF (0.4–40 ng/ml) stimulated nitrite production in OA
cartilage in a concentration dependent manner [Fig. 2(a),
600 K. Vuolteenaho et al.: Nitric oxide synthesis in OA cartilage(b)]. A non-selective NOS inhibitor, L-NIO (1 mM), pre-
vented IL-1- and TNF-induced nitrite accumulation indi-
cating that it was due to NO production. Bacterial endotoxin
(LPS) was a less potent stimulus than IL-1 and TNF and
only a concentration of 1000 ng/ml increased NO produc-
tion significantly [Fig. 2(c)]. Figure 3 shows that NO pro-
duction in response to each of these three stimuli was
linear up to 72 h follow-up. Western blot analysis was
carried out with an antibody against human iNOS, which
reacts with mouse, rat and human iNOS but not with
neuronal or endothelial NOS. In cartilage pieces treated
for 48 h with IL-1 (4 ng/ml), TNF (40 ng/ml) and LPS
(1000 ng/ml) a clear immunoreactive band was seen, and it
was of similar MW as iNOS in LPS-treated J774 murine
macrophages. OA cartilage incubated in the absence of
exogenous cytokines also expressed iNOS but at lower
level than cytokine-treated cartilage (Fig. 4).EFFECTS OF VARIOUS NOS INHIBITORS ON IL-1-INDUCED NO
PRODUCTION IN OA CARTILAGE
IL-1 stimulated nitrite production in the OA-affected
cartilage was inhibitable with various NOS inhibitors in
a dose-dependent manner showing the following order
of inhibition: 1400W (selective iNOS inhibitor)=L-NIO>L-
NMMA>L-NAME which was quite inefficient [Fig. 5(a)]. For
comparison, these four NOS inhibitors were also tested on
LPS-induced NO production in J774 macrophages and a
similar order of potency was seen [Fig. 5(b)].MECHANISMS INVOLVED IN THE IL-1-INDUCED NO PRODUCTION
IN OA CARTILAGE
The mechanisms of the IL-1 stimulated NO production
were studied by pharmacological means. Cycloheximide
(an inhibitor of protein synthesis; 10 g/ml), PDTC (an
inhibitor of the transcription factor NF-B; 100 M) and
genistein (an inhibitor of tyrosine protein kinase; 100 M)
significantly inhibited the IL-1-induced nitrite production in
osteoarthritic cartilage, while dexamethasone (10 M), PD
98059 (p42/44 MAP kinase inhibitor; 10 M) and DAHP (an
inhibitor of tetrahydrobiopterin synthesis; 1 mM) had no
effect [Fig. 6(a)]. For comparison, the effects of these
compounds were also tested on LPS-induced NO produc-
tion in J774 macrophages: NO production was respectively
inhibitable with cycloheximide, PDTC and genistein.
P42/44 MAP kinase inhibitor PD 98059 and tetrahydrobi-
opterin inhibitor DAHP caused a slight but statistically
significant inhibition on LPS-induced NO production in J774
macrophages; a similar trend not reaching statistical signifi-
cance was seen also in cartilage specimen [Fig. 6(b)]. In
the case of dexamethasone there was a clear difference in
its action on NO synthesis in osteoarthritic cartilage and
J774 macrophages. The former was insensitive for the
action of dexamethasone whereas LPS-induced NO pro-
duction in J774 cells was suppressed by 40% in the
presence of 10 M dexamethasone (Fig. 6).0
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Fig. 2. Concentration–dependent effects of cytokines IL-1 (a),
TNF (b) and bacterial endotoxin (LPS; c) on nitrite production in
osteoarthritic cartilage. Cartilage explants were cultured for 48 h
with the indicated concentrations of cytokines or LPS. Nitrite
accumulation was measured by Griess reaction and expressed as
pmol nitrite/mg tissue. Mean±S.E.M., 7 patients, with 6 replicates.
Statistical significance was calculated with repeated measures
ANOVA. *=P<0.05, **=P<0.01, ***=P<0.001 cytokine/LPS-
treated cartilage vs control or vs the effect of NOS inhibitor L-NIO
(N=7 was used in the statistical analysis). Cytokine or LPS alone,
; cytokine or LPS plus L-NIO (1 mM), .Discussion
Chondrocytes were the second cell type in which human
iNOS was cloned and characterized16 soon after it was
found in hepatocytes25. Although the cDNA sequence of
human iNOS is quite similar (88%) to the sequence of the
Osteoarthritis and Cartilage Vol. 9, No. 7 6010
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Fig. 3. The time-dependent effects of cytokines IL-1 [4 ng/ml; (a)],
TNF [40 ng/ml; (b)] and bacterial endotoxin [LPS; 1000 ng/ml; (c)]
on nitrite production in osteoarthritic cartilage. Nitrite concen-
trations were measured by Griess reaction and expressed as pmol
nitrite/mg tissue. Mean±S.E.M., 7 patients, with 6 replicates. Statisti-
cal significance was calculated with ordinary ANOVA. *** indicates
P<0.001 (N=7 was used in the statistical analysis). Control, ––;
cytokine or LPS alone, ––; cytokine or LPS plus L-NIO
(1 mM), ––.Fig. 4. iNOS expression in osteoarthritic cartilage analysed by
Western blot. Osteoarthritic cartilage specimens were incubated
for 48 h in the absence of exogenous cytokines (lane 1), with IL-1
(4 ng/ml; lane 2), TNF (40 ng/ml; lane 3) or bacterial endotoxin
(LPS 1000 ng/ml; lane 4). J774 macrophages stimulated with LPS
for 12 h (lane 5) were used as a positive control.murine macrophage iNOS, there are major differences in
the signaling mechanisms resulting in induction of NOS
between human and mouse cells. Unlike murine iNOS,
human iNOS in inflammatory and most other cells is notinducible with LPS or a single cytokine but requires a
combination of various cytokines or other more complex
treatments20,26,27. Human chondrocytes are among few
human cell types in which NO production is induced in
response to LPS alone or to a single cytokine, of which IL-1
and TNF were used in the present study. In addition to the
131 kDa human iNOS which was first described and cloned
in IL-1-treated human chondrocytes16, there are also
reports on another NO synthase found in osteoarthritic
cartilage (OA-NOS) which resembles neuronal NOS rather
than iNOS in its molecular weight and antibody binding22.
In the present study we compared the IL-1-induced NO
production in human articular cartilage to LPS-induced NO
synthesis by iNOS-pathway in murine J774 macrophages.
NO synthesis in these two cell types was quite similarly
regulated in terms of sensitivity to various NOS inhibitors
and basic signaling mechanisms involved in the transcrip-
tional activation of iNOS gene with the exception of dexa-
methasone treatment which suppressed NO production in
J774 macrophages but not in human cartilage.
The present data showed that pieces of osteoarthritic
cartilage maintained in tissue culture produced nitrite also
in the absence of exogenous cytokines or LPS. Nitrite
accumulation was partly inhibited by high (1 mM) concen-
trations of a NOS inhibitor L-NIO indicating that NO was
produced by unstimulated cartilage explants. However, it is
not clear what is the origin of the L-NIO-insensitive nitrite
that accumulated into the culture. Because L-NIO is a
non-selective NOS inhibitor and it was used in a high
concentration (1 mM), it is unlikely that the L-NIO-
insensitive nitrite formation was due to NO production. To
exclude non-specific reactivity of interfering compounds
with the Griess reagent as a reason for the L-NIO-
insensitive nitrite accumulation, nitrite measurements were
confirmed also by ozone-chemiluminescence method.
These data confirm that the part of nitrite production that
was not inhibited by a NOS inhibitor is due to nitrite
formation by other biochemical pathways or may result
from the poor penetration of the inhibitors into cartilage.
Subtotal inhibition of nitrite accumulation by various NOS
inhibitors used up to 10 mM concentrations in chondrocyte
cultures28 supports the former hypothesis. Accordingly
L-NIO was effective in the present experiments in which
cartilage was treated with TNF or LPS. In the further
studies iNOS expression in osteoarthritic cartilage was
confirmed by immunostaining of cartilage samples snap-
frozen immediately after surgery. These data, together with
the findings of Sakurai et al.19 and Amin et al.22, give direct
evidence that NOS is expressed in osteoarthritic cartilage
in vivo and suggest that NO has a role in the pathogenesis
of OA.
IL-1-induced NO production in cartilage as well as in
J774 cells was sensitive to cycloheximide suggesting that
it was dependent on de novo NOS protein synthesis.
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1000 M, .Enhanced expression of iNOS protein in cartilage pieces
exposed to IL-1, TNF or LPS was studied by Western blot
analysis using an antibody that reacts with iNOS but not
with neuronal or endothelial NOS. IL-1, TNF and LPS
induced expression of protein that stained with this anti-
body and was of similar size as the iNOS expressed in
LPS-treated J774 macrophages. These data are consistent
with the idea that the NOS isoform in osteoarthritic cartilage
is iNOS. PDTC was used to inhibit the activation of nuclear
factor-B (NF-B) which is known to be critical for the
induction of iNOS gene transcription29. NO production inIL-1-treated cartilage and LPS-treated J774 cells was
equally inhibited by PDTC suggesting that activation of
NF-B is involved in both of these activation mechanisms.
In addition, IL-1-induced NO production in osteoarthritic
cartilage and LPS-induced NO synthesis in J774 macro-
phages were similarly regulated by genistein (tyrosine
kinase inhibitor), PD 98059 (p42/44 MAP kinase inhibitor)
and DAHP (BH4 synhesis inhibitor). In the further experi-
ments we studied the sensitivity of NO production in
IL-1-treated human cartilage and LPS-treated murine J774
macrophages to various NOS inhibitors. Nitrite production
Osteoarthritis and Cartilage Vol. 9, No. 7 603by both chondrocytes and macrophages was inhibitable in
a concentration dependent manner by 1400W, L-NIO,
L-NMMA and L-NAME which showed similar order of
potency in both cell types. An iNOS selective inhibitor
1400W30 was the most potent inhibitor while L-NAME that
shows some selectivity towards the neuronal and endo-
thelial type of NOS (vs iNOS) was quite inefficient, reach-
ing a 31% and 51% inhibition at 1 mM concentrations
in articular cartilage and J774 cells, respectively. The
dose-response curves of L-NIO and L-NMMA were
in between those of 1400W and L-NAME. N-(3-
(aminomethyl)benzyl)acetamidine (1400W) is a recently
characterized tightly binding (irreversible or extremely
slowly reversible) very selective inhibitor of iNOS vs both
eNOS and nNOS30. This is the first report to show that
1400W is a potent NOS inhibitor also in IL-1-treated human
articular cartilage indicating that it penetrates well in carti-
lage tissue and may be a useful tool for further studies oncartilage NO production. Thus our results support the idea
that iNOS is the predominant isotype of nitric oxide syn-
thase involved in IL-1-induced NO production in human
osteoarthritic cartilage.
So far, iNOS is the only NOS enzyme that has been
cloned in human chondrocytes16,17. Amin et al.22 reported
evidence on a novel OA-NOS that based on its MW and
immunoreactivity in Western blot gels is close to rat brain
nNOS and different from human hepatocyte and murine
macrophage iNOS. At the moment it is not clear whether
their OA-NOS is identical to nNOS, a novel NOS isoen-
zyme or a modification of iNOS. Our data suggest that IL-1
treated osteoarthritic cartilage produce NO by iNOS path-
way. We also found iNOS expression in untreated osteo-
arthritic cartilage. These data made us to propose that
OA-NOS is merely a modification of iNOS. In addition,
difference in experimental procedures and antibodies used
may explain some differences between our results and
those reported by Amin et al.22
Dexamethasone, although used at a high concentration
(10 M) failed to inhibit NO production in IL-1-treated
cartilage whereas LPS-induced NO synthesis was inhibited
by about 40%. This is consistent with the earlier data that
chondrocyte NO production is resistant to antiinflammatory
steroids6,15,22. In other cell types glucocorticoids seem to
have variable effects. The detailed mechanisms of the
inhibitory action by glucocorticoids on NO production seen
in some cell types remain unknown but different post-
transcriptional effects have been reported31–33. Therefore
the differential action of dexamethasone on NO production
in IL-1-treated cartilage and LPS-treated macrophages
does not necessarily mean that the signalling mechanisms
leading to induction of NOS between these cell types are
different.
The present data show that osteoarthritic cartilage pro-
duces NO, and its synthesis is further enhanced by pro-
inflammatory cytokines IL-1 and TNF and by bacterial
endotoxin. A novel selective iNOS inhibitor 1400W was a
potent inhibitor of NO synthesis in human articular carti-
lage, whereas dexamethasone had no effect. IL-1-induced
NO production was dependent on protein synthesis, acti-
vation of transcription factor NF-B and tyrosine kinases
while inhibitors of p42/44 MAP kinase and tetrahydro-
biopterin synthesis were ineffective. In addition, Western
blot analysis showed iNOS in human articular cartilage,
which was of similar MW (about 131 kDa) as iNOS in
LPS-treated J774 murine macrophages. The results sug-
gest that IL-1-induced NO production in osteoarthritic car-
tilage results from NF-B sensitive and dexamethasone
insensitive expression of iNOS. These data are implicated
in the development of novel treatments against OA and RA
because there is increasing amount of evidence on the
proinflammatory and destructive effects of NO in articular
cartilage.0
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(cyclo; 10 g/ml), pyrroline dithiocarbamate (PDTC; 100 M),
genistein (gen; 100 M), PD (PD 98059; 10 M) and diamino-
hydroxypyrimidine (DAHP; 1 mM) on nitrite production in (a) osteo-
arthritic cartilage stimulated with IL-1 (4 ng/ml) for 42 h and in (b)
in J774 macrophages stimulated with LPS (100 ng/ml) for 24 h.
The tested compounds were added into the culture medium at the
beginning of the incubation. Nitrite concentrations were measured
by Griess reaction and expressed as pmol nitrite/mg tissue [in
(a)] or as mol/l [in (b)]. The results are expressed as mean±S.E.M.
In (a) samples from 6 patients each with 4 replicates (N=6). In
(b) N=6. Statistical significance was calculated with repeated
measures (a) or ordinary (b) ANOVA. ***=P<0.001 as compared to
control samples incubated in the absence of pharmacological
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